As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >

Hybrigenics Services

Genopole Campus 3 – 1 rue Pierre Fontaine – Bâtiment 1
91000 EVRY Courcouronnes – FRANCE
Phone: +33 (0)1 75 66 20 54

CEO: Jean-Christophe RAIN
Director of Chemistry: Marie-Edith Gourdel
Web Site >
Hybrigenics - Genopole's company Hybrigenics - Genopole's company

#R&D Services and Products #Biomanufacturing / Pharmaceutical Services

  • Protein interactions
  • Drug target deconvolution
  • Molecular glues
  • Nanobodies

Field of Activity

Hybrigenics Services proposes fee-for-services R&D support. It provides innovative technological platforms for
i) protein interaction studies (protein-protein, drug-protein, mechanisms of action) and
ii) selection and validation of VHH antibodies.

Launched in 1998 as Hybrigenics SA, a first spin-off from Institut Pasteur Paris, the company optimizes a yeast two-hybrid system for protein-protein interaction discovery. Its services activities were launched in 2003. Hybrigenics Services has developed new versions for drug discovery (2013, mechanism of action; 2019 molecular glues/PROTACs). A novel nanobody selection platform was launched in 2016.
The company is an independent entity since 2017.
Hybrigenics Services has technological platforms for the:

  • discovery of novel protein-protein interactions, Protein network (ULTImate Y2H™)
  • identification of small molecule interactions, e.g., proteins, their therapeutic targets, elucidation of mechanisms of action for drug candidates (ULTImate YChemH™)
  • identification of PPIs induced by small molecules (molecular glues, PROTACs, etc.) for targeted protein degradation (TPD) & stabilization projects (ULTImate Y2HChem™)
  • selection and validation of VHH antibodies (HYBRIBODY™)


  • The company counts 3,000 clients and partners across the globe and the spectrum of scientific domains (pharma, agriculture, cosmetics, basic research). Biotechs from start-ups to large corporations in pharma and agriculture, academic research.
  • Hybrigenics Services has established scientific and technological renown with more than 500 publications on its results in top-ranked journals
  • Hybrigenics Services completes more than 150 mostly confidential service contracts yearly, with pricings ranging from several thousand to several hundred thousand euros

Hybrigenics Services seeks partnerships with biotechs, start-ups, the pharmaceutical industry, and actors in agricultural sciences and academic research.

  • Further Information

    2 Patents
    30 Staff Members

    • Field-leading Y2H screening platform with a very large collection (130) of cDNA libraries (45 species: human, animals, plants, model organisms, bacteria, etc.), exhaustive screening and integrated bioinformatics.
    • Nanobodies: Animal-free technique to select synthetic VHH antibodies from a patented bank of 3X10⁹ humanized camalid VHHs.
    • 25 years of experience
    • 10,000 Y2H and associated screenings

    Innovation Assets:
    Continuously listening to the needs of researchers to bring them new, pertinent solutions.
    Other facts:
    Hybrigenics Services is a private, management/employee-owned company. It practices corporate social responsibility. Hybrigenics Services measured its carbon footprint in 2021 and deployed specific actions to reduce its environmental impact.

Genopole’s Companies

#R&D Services and Products

In same field

Alt Biotech - Genopole's Company Gene.iO#3

Alt Biotech

Alt Biotech offers an innovative bioproduction platform for non-therapeutic recombinant proteins: productive, scalable, with low environmental impact

Quibiotic - Projet Shaker


Quibiotic develops three molecular synthesis platforms aimed at innovatively modifying β-lactam rings for new anti-infectives.

Maison M - Startup génopolitaine

Maison M

Personalized and sustainable Cosmetic House inspired by various and unique beauties. The innovative Maison M lipstick delivers any shade customized by its user.

Adlin - Entreprise génopolitaine - #IA Biotech

Adlin Science

ADLIN Science is a mission-driven company that strives to transform the life sciences sector by providing solutions to bring together public actors (institutes, hospitals, universities) and private actors (biotechs, pharma). Our innovative approach is to develop the first decentralized Digital Research Environment (fundamental, translational, and clinical) dedicated to the entire public and private ecosystem. ADLIN is the scientific trusted third-party among all actors in the sector with the ambition to accelerate innovation in healthcare while participating in research financing.

Altar - entreprise génopolitaine - intégre le groupe Ginko Bioworks


Ginkgo Bioworks is a specialist in the conception and operation of automated fluidic continuous culture systems for adaptive laboratory evolution and the development of microbial strains for industry.

Xentech - Genopole Company


XenTech is an innovative biotech company specialized in the preclinical evaluation of cancer drugs and the identification of biomarkers and therapeutic targets.

Polytheragene - Genopole's Company


Manufacture and sale of new high performance transfecting agents for gene therapy, high-throughput screening and biomanufacturing. Cosmetic and therapeutic molecules from plant biomass.

Phinc Development - Genopole's Company

PhinC Development

PhinC Development brings its expertise to small and mid-sized biotechs and pharmaceutical companies looking to advance their early-stage drug research.

New england Biolabs - Genopole's Compny - 50 Years logo

New England Biolabs France

New England Biolabs is a private company manufacturing reagents for the life science industry particularly focused on products for genomic research.

logo abcell Bio - Genopole's Companie


Abcell-bio is a laboratory specializing in the isolation of human hematopoietic stem cells and primary cells derived from perinatal tissue and cord blood.

View all >
With the support from
Région île de France